Skip to main content
47°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals Inc
(NQ:
TARS
)
32.04
-0.17 (-0.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Tarsus Pharmaceuticals Inc
< Previous
1
2
Next >
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
February 29, 2024
Via
Benzinga
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
February 28, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Tarsus Pharmaceuticals's Earnings: A Preview
February 26, 2024
Via
Benzinga
Tarsus Pharmaceuticals - Mixed Projections
February 02, 2024
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
Via
Talk Markets
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
January 29, 2024
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: Tarsus Pharmaceuticals Q3 Earnings
November 09, 2023
Via
Benzinga
Earnings Preview: Tarsus Pharmaceuticals
November 08, 2023
Via
Benzinga
Expert Ratings for Tarsus Pharmaceuticals
September 11, 2023
Via
Benzinga
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
December 21, 2023
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.
Via
Investor's Business Daily
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 10, 2023
Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.
Via
Benzinga
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals
August 14, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
July 26, 2023
Via
Benzinga
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
December 15, 2022
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
November 10, 2023
Via
Benzinga
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
November 10, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
July 31, 2023
Via
Benzinga
Earnings Scheduled For November 9, 2023
November 09, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via
Benzinga
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
July 25, 2023
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 25, 2023
Via
Benzinga
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 25, 2023
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
Via
Benzinga
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
July 20, 2023
The company's lead therapy is getting close to the finish line of FDA approval.
Via
The Motley Fool
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 20, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.
Via
Benzinga
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday
July 20, 2023
U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
July 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).
Via
Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...
Via
Benzinga
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
February 23, 2023
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.